| ID | 1180 |
| Name of the vaccine | NDV-3 |
| Microbe | Bacteria |
| Disease name | Methicillin-Resistant Staphylococcus aureus (MRSA) |
| Name of bacteria | Staphylococcus aureus |
| Type of vaccine | Recombinant |
| Nucleic acid content | Circular DNA |
| Age | 18 to 50 years |
| Description of the vaccine | Recombinant protein vaccine. |
| Name of the manufacturer | NovaDigm Therapeutics, Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | 2011 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Two doses, 6 months apart at two dose levels. |
| Mechanism of action | Increases in CD3+ T-cell and neutrophil infiltration and IL-17A, IL-22 and host defence peptide expression. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Alum |
| Repurposing | For Candida. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 25489065 |
| Clinical trial number | NCT01273922 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|